Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Smith

Family Medicine Grand Ledge, MI Medical Doctor

NPI 1275623662 CMS profile 238826

1035 Charlevoix Dr, Suite 100, Grand Ledge, MI 48837

Open in the dashboard

General payments

$5,760

384 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Smith of Grand Ledge, MI is reported in the CMS Open Payments database as having received $5,760 across 384 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 2
2024 General $52 3
2023 General $915 77
2022 General $2,306 93
2021 General $677 62
2020 General $453 50
2019 General $1,325 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Smith
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to David Smith were reported at $33. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year David Smith Family Medicine median Middle half National median
2019 $1,325 $150 $41–$543 $163
2020 $453 $120 $32–$415 $114
2021 $677 $137 $35–$551 $132
2022 $2,306 $137 $37–$512 $149
2023 $915 $149 $42–$545 $160
2024 $52 $156 $44–$560 $164
2025 $33 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,558 178 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $1,168 7 payments
  3. AbbVie, Inc. $624 63 payments
  4. AstraZeneca Pharmaceuticals LP $332 8 payments
  5. Lilly USA, LLC $315 26 payments
  6. Amgen Inc. $269 18 payments
  7. Pfizer Inc. $267 14 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $137 8 payments
  9. Janssen Pharmaceuticals, Inc $113 4 payments
  10. GlaxoSmithKline, LLC. $99 7 payments
  11. Other $878 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,645 381 payments
  2. Consulting Fee $1,082 1 payment
  3. Education $34 2 payments
Products named General payments · program years 2019–2025
  1. Kerendia $1,168 7 payments
  2. Ozempic $1,132 133 payments
  3. RYBELSUS $802 112 payments
  4. VRAYLAR $443 52 payments
  5. TRULICITY $198 17 payments
  6. Repatha $176 12 payments
  7. FARXIGA $173 4 payments
  8. Otezla $164 11 payments
  9. COLOGUARD $139 5 payments
  10. Wegovy $123 9 payments
  11. Other $3,183 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

384 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record